Clinical Trial

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2024 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to evaluate the efficacy and safety of avapritinib in relapsed or refractory pediatric core binding factor acute myeloid leukemia with KIT mutation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-12.
Trial Details
NCT Number NCT06316960
Lead Sponsor Children's Hospital of Soochow University
Conditions AML, Childhood, Relapse/Recurrence, Refractory AML, Core Binding Factor Acute Myeloid Leukemia, C-KIT Mutation
Enrollment 50 participants
Start Date 2024-03-01
Primary Completion 2026-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2024-08-22